Skip to content

Study · Not a test of the peptide alone · 2021

6 results

Effect of Medical and Surgical Interventions on α-Cell Function in Dysglycemic Youth and Adults in the RISE Study.

Kahn SE, Edelstein SL, Arslanian SA, Barengolts E, Caprio S, Ehrmann DA, Hannon TS, Marcovina S, Mather KJ, Nadeau KJ, Utzschneider KM, Xiang AH, Buchanan TA

Diabetes care16 Jun 2021Cited by 4 (Europe PMC)

PMID34135015 (opens in a new tab)PMCIDPMC8740921 (opens in a new tab)DOI10.2337/dc21-0461 (opens in a new tab)PepBankPUB-34135015
Source linkPubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 01HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In dysglycemic adults, liraglutide plus metformin reduced fasting glucagon at 12 months, while metformin, glargine then metformin, and placebo did not.

    In plain wordsIn adults with early blood sugar problems, liraglutide plus metformin lowered fasting glucagon at 12 months. Metformin alone and placebo did not.

    Peptide
    Liraglutide
    Outcome
    DecreaseFasting glucagon at 12 months
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Endocrine and hormones

    Source sentences

    Summary
    No change in fasting glucagon, steady-state glucagon, or AGR was seen at 12 months following treatment with MET or G/M (in youth and adults) or PLAC (in adults). In contrast, L+M reduced these measures at 12 months (all P ≤ 0.005), which was maintained 3 months after treatment withdrawal (all P < 0.01).
    2 context sentences
    Summary · context
    Glucagon was measured in three randomized, parallel, clinical studies: 1) 91 youth studied at baseline, after 12 months on metformin alone (MET) or glargine followed by metformin (G/M), and 3 months after treatment withdrawal; 2) 267 adults studied at the same time points and treated w…
    Summary · context
    Fasting glucagon, glucagon suppression by glucose, and acute glucagon response (AGR) to arginine were assessed during hyperglycemic clamps.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 02HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In dysglycemic adults, liraglutide plus metformin reduced steady-state glucagon at 12 months, while metformin, glargine then metformin, and placebo did not.

    In plain wordsIn adults with early blood sugar problems, liraglutide plus metformin lowered glucagon during a sugar clamp at 12 months. Metformin alone and placebo did not.

    Peptide
    Liraglutide
    Outcome
    DecreaseSteady-state glucagon at 12 months
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Endocrine and hormones

    Source sentences

    Summary
    No change in fasting glucagon, steady-state glucagon, or AGR was seen at 12 months following treatment with MET or G/M (in youth and adults) or PLAC (in adults). In contrast, L+M reduced these measures at 12 months (all P ≤ 0.005), which was maintained 3 months after treatment withdrawal (all P < 0.01).
    2 context sentences
    Summary · context
    Glucagon was measured in three randomized, parallel, clinical studies: 1) 91 youth studied at baseline, after 12 months on metformin alone (MET) or glargine followed by metformin (G/M), and 3 months after treatment withdrawal; 2) 267 adults studied at the same time points and treated w…
    Summary · context
    Fasting glucagon, glucagon suppression by glucose, and acute glucagon response (AGR) to arginine were assessed during hyperglycemic clamps.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  3. 03HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In dysglycemic adults, liraglutide plus metformin reduced the acute glucagon response to arginine at 12 months, while metformin, glargine then metformin, and placebo did not.

    In plain wordsIn adults with early blood sugar problems, liraglutide plus metformin lowered the glucagon response to arginine at 12 months. Metformin alone and placebo did not.

    Peptide
    Liraglutide
    Outcome
    DecreaseAcute glucagon response to arginine at 12 months
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Endocrine and hormones

    Source sentences

    Summary
    No change in fasting glucagon, steady-state glucagon, or AGR was seen at 12 months following treatment with MET or G/M (in youth and adults) or PLAC (in adults). In contrast, L+M reduced these measures at 12 months (all P ≤ 0.005), which was maintained 3 months after treatment withdrawal (all P < 0.01).
    2 context sentences
    Summary · context
    Glucagon was measured in three randomized, parallel, clinical studies: 1) 91 youth studied at baseline, after 12 months on metformin alone (MET) or glargine followed by metformin (G/M), and 3 months after treatment withdrawal; 2) 267 adults studied at the same time points and treated w…
    Summary · context
    Fasting glucagon, glucagon suppression by glucose, and acute glucagon response (AGR) to arginine were assessed during hyperglycemic clamps.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  4. 04HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In dysglycemic adults, the reduction in glucagon measures with liraglutide plus metformin was maintained 3 months after treatment withdrawal.

    In plain wordsIn adults with early blood sugar problems, the lower glucagon seen with liraglutide plus metformin was still present 3 months after stopping treatment.

    Peptide
    Liraglutide
    Outcome
    DecreaseGlucagon measures 3 months after treatment withdrawal
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Endocrine and hormones

    Source sentences

    Summary
    In contrast, L+M reduced these measures at 12 months (all P ≤ 0.005), which was maintained 3 months after treatment withdrawal (all P < 0.01).
    2 context sentences
    Summary · context
    Glucagon was measured in three randomized, parallel, clinical studies: 1) 91 youth studied at baseline, after 12 months on metformin alone (MET) or glargine followed by metformin (G/M), and 3 months after treatment withdrawal; 2) 267 adults studied at the same time points and treated w…
    Summary · context
    Fasting glucagon, glucagon suppression by glucose, and acute glucagon response (AGR) to arginine were assessed during hyperglycemic clamps.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  5. 05HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In dysglycemic adults, glucagon suppression during oral glucose tolerance tests was greater with liraglutide plus metformin.

    In plain wordsIn adults with early blood sugar problems, glucagon fell more during a sugar drink test with liraglutide plus metformin.

    Peptide
    Liraglutide
    Outcome
    IncreaseGlucagon suppression during OGTT
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Endocrine and hormones

    Source sentences

    Summary
    Similarly, glucagon suppression during OGTTs was greater with L+M and LB.
    2 context sentences
    Summary · context
    Glucagon was measured in three randomized, parallel, clinical studies: 1) 91 youth studied at baseline, after 12 months on metformin alone (MET) or glargine followed by metformin (G/M), and 3 months after treatment withdrawal; 2) 267 adults studied at the same time points and treated w…
    Summary · context
    Fasting glucagon, glucagon suppression by glucose, and acute glucagon response (AGR) to arginine were assessed during hyperglycemic clamps.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  6. 06HumanNot a test of Liraglutide aloneRandomized controlled trialMechanism

    In dysglycemic adults, the glucagon effects of liraglutide plus metformin were largely associated with weight loss.

    In plain wordsIn adults with early blood sugar problems, the glucagon changes with liraglutide plus metformin were largely linked to weight loss.

    Peptide
    Liraglutide
    Outcome
    Not applicableAssociation of glucagon change with weight loss
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Endocrine and hormones

    Source sentences

    Summary
    Linear models demonstrated that treatment effects on glucagon with L+M and LB were largely associated with weight loss.
    2 context sentences
    Summary · context
    Glucagon was measured in three randomized, parallel, clinical studies: 1) 91 youth studied at baseline, after 12 months on metformin alone (MET) or glargine followed by metformin (G/M), and 3 months after treatment withdrawal; 2) 267 adults studied at the same time points and treated w…
    Summary · context
    Fasting glucagon, glucagon suppression by glucose, and acute glucagon response (AGR) to arginine were assessed during hyperglycemic clamps.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT01779362

RISE Adult Medication Study

RISE Study Groupn = 267Apr 2013 to Aug 2019

Prediabetes · Type 2 Diabetes

Trial pageClinicalTrials.govUpdated 11 May 2023

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.